Corporate Banner
Satellite Banner
Scientific Community
Become a Member | Sign in
Home>News>This Article

Deadliest Cancers May Respond to New Drug Treatment Strategy

Published: Monday, July 22, 2013
Last Updated: Monday, July 22, 2013
Bookmark and Share
Researchers have found a way to knock down cancers caused by a tumor-driving protein called “myc,” paving the way for clinical trials.

Myc acts somewhat like a master switch within cells to foster uncontrolled growth. Until now, it has been impossible to target with drugs.

The discovery of an unexpected biochemical link within tumor cells should lead to clinical trials for experimental drug treatments that indirectly target myc and that already are being evaluated in human studies, the researchers said.

UCSF Helen Diller Family Comprehensive Cancer Center scientists led by Davide Ruggero, PhD, and Kevan Shokat, PhD, used one such drug to stop tumor growth in a mouse model of myc-driven lymphoma and multiple myeloma types of blood cancer.

Their study is published online in Proceedings of the National Academy of Sciences (PNAS).

Previously Ineffective Drug Therapies

Unrestrained myc activity is a major player in many cancers, including cancers of the lung, colon, breast, brain, prostate and blood. Abnormal myc in cancer often is associated with poor treatment outcomes, including death.

Although other cancer-associated proteins have been successfully attacked with targeted therapies in recent years, the myc protein has continued to elude efforts to develop drugs that target it. In the PNAS paper, the UCSF researchers describe how they found a way to indirectly, but effectively, target myc-driven tumors.

The researchers discovered that cancerous myc can be thwarted by treatment that targets a specific function performed by another protein, called mTOR. The mTOR protein is part of a different biochemical pathway controlling protein production and metabolism, one that also often takes a crooked turn in tumors.
Protein Production in Cancer Is Promising Target

Ruggero has for several years been probing the ability of tumor cells to make extraordinary amounts of protein to sustain their rapid growth and immortality. He also explores ways to target this excess protein production in cancer.

“One of the major and immediate downstream effects of myc activation is a dramatic increase in the capacity of affected cells to make protein,” Ruggero said “This, in turn, leads to increased cell survival and proliferation, and to unstable genomes that foster additional mutations that turn these abnormal cells into tumor cells.”

In earlier studies, Ruggero found that myc not only drives protein production, but also that myc-driven cancer cells become absolutely dependent upon this ability to make abnormal amounts of protein. When he genetically manipulated myc-driven cancer cells to slow protein production, they committed suicide, as abnormal cells are supposed to do for the greater good.

“Tumors become addicted to excessive protein production, and mutant myc itself seems to depends on it,” Ruggero said.

When present in tumors, both abnormal myc and abnormal mTOR are known to be able to rev up protein production and to foster cell growth. However, it was unclear how this myc-driven protein production could be therapeutically targeted, Ruggero said.

In the new study, the UCSF team discovered that myc relies in part on mTOR to secure its protein supply. First mTOR disables a protein that acts as a tumor suppressor, called 4EBP1. The disabling of 4EBP1 releases normal constraints on protein production within the cell. Previously, other molecular actors had been thought to play leading roles in triggering excess protein production directed by myc.

“The discovery that myc converges on the same downstream path as mTOR was surprising to us,” Ruggero said.

Zeroing In on the mTOR Protein

The researchers targeted mTOR with an experimental drug based on a prototype first designed by Shokat, a chemist and an expert in designing molecules to target this type of protein, called a kinase. In the mice, drug treatment caused a shutdown of excess protein production in myc-driven cancer cells. Myc no longer was able to drive tumor growth, cancer cells committed suicide, and the treated mice survived longer.

“In the clinic, we frequently test myc levels in patients’ tumors, for disease prognosis and to predict treatment response,” said Michael Pourdehnad, MD, a clinical oncologist at UCSF with Ruggero's lab and the first author of the study. “Yet, the lack of specific therapies to target myc-driven cancers is frustrating. Our discovery may provide a novel solution for these patients.”

“We are excited by the work of Dr. Pourdehnad and colleagues and believe these results are an important advance in understanding the role of myc pathway dysregulation in multiple myeloma, and ultimately allow for the development of therapeutic strategies to address it,” said Jeffrey Wolf, MD, a UCSF blood disorder specialist and director of the Stephen and Nancy Grand Multiple Myeloma Translational Initiative at UCSF, a sponsor of the research.

The drug used in the study, called MLN0128, is made by Millennium, an independently operated subsidiary of Takeda Pharmaceutical Co., Ltd., based in Cambridge, Mass., and it is being evaluated in clinical trials to treat a variety of cancers. It had not previously been viewed as a weapon against myc-driven tumors, according to the UCSF researchers.

Currently sold drugs directed against mTOR do not inhibit its ability to target 4EBP1, which Ruggero refers to as a “master regulator” of protein production.

“This is a unique therapeutic approach to make myc druggable in the clinic,” Shokat said.

Additional co-authors of the study are UCSF graduate students Morgan Truitt and Greg Ducker, and Imran Siddiqi, MD, PhD, a pathologist at the University of Southern California. Additional funds for the research were awarded by the National Institutes of Health (Grants R01CA154916 and R01 CA140456), and the Waxman Foundation. Shokat is supported by the Howard Hughes Medical Institute and Truitt is supported in part by an HHMI fellowship. The authors declare no conflict of interest in this research.

UCSF is a leading university dedicated to promoting health worldwide through advanced biomedical research, graduate-level education in the life sciences and health professions, and excellence in patient care.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Clearest Ever Images of Enzyme that Plays Key Roles in Aging, Cancer
UCLA-led research on telomerase could lead to new strategies for treating disease
Monday, October 19, 2015
Crop Cure
Scientists in new center to use medical research techniques to help food crops withstand drought and climate change.
Friday, October 16, 2015
Industry-Sponsored Academic Inventions Spur Increased Innovation
Analysis questions assumption that corporate support skews science toward inventions that are less useful than those funded by the government or non-profit organizations.
Monday, March 24, 2014
Structure of Key Pain-Related Protein Unveiled
In a technical tour de force, scientists have determined, at near-atomic resolution, the structure of a protein that plays a central role in the perception of pain and heat.
Friday, December 06, 2013
Chemical Signature for Fast Form of Parkinson's Found
The physical decline experienced by Parkinson's disease patients eventually leads to disability and a lower quality of life.
Monday, November 25, 2013
New Insights into How Proteins Regulate Genes
Researchers have developed a new way to parse and understand how special proteins called "master regulators" read the genome, and consequently turn genes on and off.
Monday, October 21, 2013
Cell Growth Discovery Has Implications for Targeting Cancer
The way cells divide to form new cells is controlled in previously unsuspected ways.
Monday, October 21, 2013
Discovery Could Lead to Saliva Test for Pancreatic Cancer
The disease is typically diagnosed through an invasive and complicated biopsy.
Tuesday, October 15, 2013
Tuberculosis and Parkinson’s Disease Linked by Unique Protein
UCSF researchers seek way to boost protein to fight both diseases.
Wednesday, September 11, 2013
Effects of Parkinson’s Disease Mutation Reversed in Cells
UCSF study used chemical commonly found in anti-wrinkle cream.
Friday, August 23, 2013
Dentistry School Receives $5M to Study Saliva Biomarkers
Imagine having a sample of your saliva taken at the dentist's office, and then learning within minutes whether your risk for stomach cancer is higher than normal.
Thursday, August 15, 2013
Scientists Devise Innovative Method to Profile and Predict the Behavior of Proteins
A class of proteins that are made up of multiple, interlocking molecular components, enzymes perform a variety of tasks inside each cell.
Friday, August 09, 2013
Immune System Molecule Promotes Tumor Resistance
A team of scientists has shown for the first time that a signaling protein involved in inflammation also promotes tumor resistance to anti-angiogenic therapy.
Tuesday, August 06, 2013
Failure to Destroy Toxic Protein Contributes to Progression of Huntington’s Disease
Gladstone-led study also finds target that boosts protein clearance, prolongs cell life.
Tuesday, July 23, 2013
Brain Anomolies are Potential Biomarkers for Autism
Brain anomalies may serve as potential biomarkers for the early identification of the neurodevelopmental disorder.
Wednesday, July 10, 2013
Scientific News
Non-Disease Proteins Kill Brain Cells
Scientists at the forefront of cutting-edge research into neurodegenerative diseases such as Alzheimer’s and Parkinson’s have shown that the mere presence of protein aggregates may be as important as their form and identity in inducing cell death in brain tissue.
Closing the Loop on an HIV Escape Mechanism
Research team finds that protein motions regulate virus infectivity.
New Class of RNA Tumor Suppressors Identified
Two short, “housekeeping” RNA molecules block cancer growth by binding to an important cancer-associated protein called KRAS. More than a quarter of all human cancers are missing these RNAs.
Gut Microbes Signal to the Brain When They're Full
Don't have room for dessert? The bacteria in your gut may be telling you something.
Turning up the Tap on Microbes Leads to Better Protein Patenting
Mining millions of proteins could become faster and easier with a new technique that may also transform the enzyme-catalyst industry, according to University of California, Davis, researchers.
Exploring the Causes of Cancer
Queen's research to understand the regulation of a cell surface protein involved in cancer.
Measuring microRNAs in Blood to Speed Cancer Detection
A simple, ultrasensitive microRNA sensor holds promise for the design of new diagnostic strategies and, potentially, for the prognosis and treatment of pancreatic and other cancers.
Novel Proteins Linked to Huntington's Disease
University of Florida Health researchers have made a new discovery about Huntington's disease, showing that the gene that causes the fatal disorder makes an unexpected "cocktail" of mutant proteins that accumulate in the brain.
Enzyme Critical to Maintaining Telomere Length Discovered
New method expected to speed understanding of short telomere diseases and cancer.
New Method Identifies Up to Twice as Many Proteins and Peptides
An international team of researchers developed a method that identifies up to twice as many proteins and peptides in mass spectrometry data than conventional approaches.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos